Skip to main content

Table 1 Composition of study cohorts

From: Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection

Patient ID Cohort Doses received EOT → B× time lapse (hours) Histology ΔCD8 ΔCD56 Tumor at EOT
P5 Imiq q12 × 2 days 4 13 Nodular 0 -1 +
P6 Imiq q12 × 2 days 4 14 Undetermined 0 0 +
P17 Imiq q12 × 2 days 4 36 Undetermined NE NE -
P18 Imiq q12 × 2 days 4 33 Nodular +1 0 +
P30 Imiq q12 × 2 days 4 16 Nodular 0 0 -
P38 Imiq q12 × 2 days 4 17 Nodular 0 0 +
P231 Imiq q12 × 2 days 4 22 Undetermined +1 0 +
P10 Vehic q12 × 2 days 4 12 Nodular 0 0 +
P23 Vehic q12 × 2 days 2 15 Nodular +2 0 +
P26 Vehic q12 × 2 days 4 45 Nodular 0 0 +
    Mean ± SD = 22 ± 11.5     
P1 Imiq q12 × 4 days 8 8 Nodular 0 0 +
P21 Imiq q12 × 4 days 8 41 Nodular 0 +1 +
P22 Imiq q12 × 4 days 8 11 Nodular +1 0 -
P40 Imiq q12 × 4 days 8 17 Nodular +1 +1 -
P42 Imiq q12 × 4 days 8 3 Undetermined +3 0 -
P129 Imiq q12 × 4 days 8 19 Nodular +1 0 +
P135 Imiq q12 × 4 days 8 21 Superficial +1 +1 -
P41 Vehic q12 × 4 days 8 28 Nodular +1 0 +
P134 Vehic q12 × 4 days 8 19 Nodular +2 0 +
P8 Vehic q12 × 4 days 8 20 Nodular 0 0 +
P20 Vehic q12 × 4 days 8 16 Superficial 0 0 +
    Mean ± SD = 18 ± 10.2     
P11 Imiq q24 × 4 days 4 26 Nodular 0 +1 +
P28 Imiq q24 × 4 days 3 20 Nodular NE NE +
P112 Imiq q24 × 4 days 4 44 Nodular 0 0 +
P214 Imiq q24 × 4 days 4 51 Nodular +2 +1 -
P4 Vehic q24 × 4 days 4 16 Superficial NE -1 -
P13 Vehic q24 × 4 days 4 30 Nodular 0 0 +
P36 Vehic q24 × 4 days 4 25 Superficial 0 0 +
    Mean ± SD = 30 ± 12.8     
P233 Imiq q24 × 8 days 8 32 Undetermined 0 +1 +
P132 Imiq q24 × 8 days 8 159 Undetermined 0 +2 -
P24 Imiq q24 × 8 days 8 48 Superficial +1 0 -
P3 Imiq q24 × 8 days 8 12 Undetermined -1 0 +
P2 Vehic q24 × 8 days 8 6 Undetermined 0 -1 +
P15 Vehic q24 × 8 days 8 21 Nodular 0 0 +
P27 Vehic q24 × 8 days 8 26 Nodular NE NE +
P137 Vehic q24 × 8 days 8 11 Superficial 0 0 +
    Mean ± SD = 39 ± 50.3     
  1. Punch biopsies are labeled according to patient number (P1 to P42) and timing of excision: PB0, pre-enrollment; PB1 and PB2, pre-treatment; PB3 and PB4, post-treatment. Biopsies from patients replacing drop-outs were labeled one digit to the serial number (that is, P101 to P142 or P201 to P242. PB1 and PB3 were collected for total RNA isolation; PB2 and PB4 for IHC. Undetermined refers to a BCC histology in-between superficial and nodular. ΔCD8 and ΔCD56 scores differences in infiltrate between EOT and pre-treatment samples (see Materials and methods). Tumor at EOT: identifiable (+) or not identifiable (-) tumor cells in the hematoxylin eosin stained EOT biopsy. Imiq, imiquimod; NE, not evaluated; Vehic, vehicle.